Independent SMO (Site Management Organization) Panthera Biopartners has opened its first clinical trials site in Preston, Lancashire, UK. The clinical trial site, which is the first of a number of planned sites in the UK and overseas, is already involved in implementing trials on behalf of its clients from CROs and pharma companies.
Panthera is initially aiming at recruiting patients and running clinical trials in therapy areas which are traditionally managed in primary care including cardiac disease, allergies, migraine, osteoarthritis, osteoporosis, diabetes etc.
In the New Year the company is looking at NASH in primary care and Oncology and Neurology for secondary care.
The Panthera team has very wide experience in providing feasibility, recruitment, running of clinical trials and retention across a broad range of therapy areas. All the healthcare staff at the Preston Panthera site are GCP trained with considerable experience in the recruiting of patients and running of clinical trials.
“It has been so encouraging talking to CROs and major pharma companies. They have really welcomed the entry of Panthera Biopartners as an independent SMO which incorporates new technology into the running of clinical trials and the recruitment of patients,” Dr. Ian Smith, Founder and Medical Director of Panthera said. “We plan to have a number of sites up and running by the first quarter of 2020 with an ongoing expansion program across the UK and overseas.”